{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:33:07Z","timestamp":1759483987000},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"918","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,4,1]]},"abstract":"Abstract<\/jats:title>\n \n Aims<\/jats:title>\n To investigate prescribing patterns to prevent steroid induced osteoporosis. To compare prophylactic prescribing with National Osteoporosis Society (NOS) guidelines.<\/jats:p>\n <\/jats:sec>\n \n Method<\/jats:title>\n All patients (n=92) taking oral corticosteroids admitted to general medical wards at a district general hospital were prospectively investigated over a nine month period.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Variations from recommended management were revealed. Altogether 64.7% of all inpatients who qualified for prophylaxis for steroid induced osteoporosis were not provided with any suitable agent. It was also found that 21.6% of those who qualified for treatment received a bisphosphonate, the only treatment currently licensed for preventing steroid induced osteoporosis. Of those prescribed prophylactic treatment, a bisphosphonate was selected for 39.3%, hormone replacement therapy was given to 25.0%, and 35.7% received treatment that is not recommended in NOS guidelines.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This study revealed substantial variations from NOS guidelines. It is suggested that osteoporosis prophylaxis during steroid treatment is promoted by local hospital guidelines, hospital and community pharmacists, audit, and general practitioners.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/pmj.78.918.242","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:30:44Z","timestamp":1027765844000},"page":"242-243","source":"Crossref","is-referenced-by-count":23,"title":["Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe"],"prefix":"10.1093","volume":"78","author":[{"given":"S R","family":"Hart","sequence":"first","affiliation":[{"name":"St Thomas\u2019 Hospital , London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Green","sequence":"additional","affiliation":[{"name":"Royal Sussex County Hospital , Brighton, Sussex"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2002,4,1]]},"reference":[{"key":"2023042416165230900_R1","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199708073370603","article-title":"Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis","volume":"337","author":"Adachi","year":"1997","journal-title":"N Engl J Med"},{"key":"2023042416165230900_R2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"2023042416165230900_R3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/jbmr.5650051204","article-title":"Corticosteroid effects on proximal femur bone loss","volume":"5","author":"Sambroke","year":"1990","journal-title":"J Bone Miner Res"},{"key":"2023042416165230900_R4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2796.1998.00408.x","article-title":"A UK consensus group on management of glucocorticoid-induced osteoporosis: an update","volume":"244","author":"Eastell","year":"1998","journal-title":"J Intern Med"},{"key":"2023042416165230900_R5","volume-title":"Guidance on the prevention and management of corticosteroid-induced osteoporosis","author":"National Osteoporosis Society","year":"1998"},{"key":"2023042416165230900_R6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bmj.313.7053.344","article-title":"Use of oral corticosteroids in the community: a cross sectional study","volume":"313","author":"Walsh","year":"1996","journal-title":"BMJ"},{"key":"2023042416165230900_R7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/ard.54.1.66","volume":"54","author":"Peat","year":"1995","journal-title":"J Rheum Dis"},{"key":"2023042416165230900_R8","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0140-6736(05)60740-4","article-title":"Management of corticosteroid-induced osteoporosis","volume":"352","author":"Stevenson","year":"1998","journal-title":"Lancet"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/78\/918\/242\/50039875\/postgradmedj-78-242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/78\/918\/242\/50039875\/postgradmedj-78-242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T16:19:49Z","timestamp":1682353189000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/78\/918\/242\/7038980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4,1]]},"references-count":8,"journal-issue":{"issue":"918","published-online":{"date-parts":[[2002,4,1]]},"published-print":{"date-parts":[[2002,4,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pmj.78.918.242","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,4]]},"published":{"date-parts":[[2002,4,1]]}}}